Pharmaceuticals & Biotech German Community

Item 1 – Business (what the company does) �Johnson & Johnson is a New Jersey–incorporated healthcare holding company with operating subsidiaries in virtually all countries and ~138,200 employees focused on human health and well‑being. �Operates in two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices and technologies).Read more

Perspectivas de Mercado Olhando para o horizonte de 2026 e além, a Bayer AG emerge como uma empresa em transição estratégica, navegando por desafios persistentes enquanto aposta em inovação e eficiência operacional para impulsionar uma recuperação sustentável. Após um 2025 marcado por declínios em lucros e pressões litigiosas, a companhia projeta um retorno ao crescimento de lucros a partir de 2026, impulsionado por um pipeline robusto em farmacêuticos, otimizações em Crop Science e uma reestruturação interna que visa economias significativas.Read more

Ecco cosa dicono gli utili di Novo Nordisk del Q4 2024 Nonostante le azioni si trovino ai minimi degli ultimi 15 mesi e il sentiment generale sia un po' ribassista, i dati del Q4 offrono spunti interessanti. Il colosso farmaceutico europeo ha registrato un incremento del 30,1% nelle vendite , raggiungendo 11,48 miliardi EUR, superando così le attese.Read more

Demand is shifting toward more complex injectable medicines, and SCHOTT Pharma is betting that bigger capacity and closer partnerships will make its drug packaging and delivery products harder to replace. The upside comes from higher-value, more sustainable offerings, but weak demand in some core lines, heavy spending, and leadership changes could slow progress.Read more

Gerresheimer is betting that a big acquisition and a push into more advanced drug packaging can lift profits as production upgrades come online. The catch is that integration hiccups, uneven cash flow, and weaker demand in one part of the business could get in the way.Read more

Heidelberg Pharma is betting on a new way to deliver cancer drugs that aims to punch through tough-to-treat tumors, with early trial results for its lead program drawing attention. The upside is big if its main study keeps going well and new drug candidates follow, but funding and setbacks in trials or manufacturing could quickly change the story.Read more

Merck KGaA is leaning harder into its faster-growing lab and healthcare businesses, using deals, new medicines, and digital tools to rebuild growth and confidence. But a slow electronics recovery, shifting research budgets, and looming patent losses could make that turnaround bumpier than it looks.Read more

Evotec aims to become a go-to partner for drug makers by using AI, large patient data, and faster biologics manufacturing to speed up early research and win longer-term partnerships. The catch is that weaker biotech funding, tougher competition, and rapid tech shifts could slow demand and squeeze profits just as the company tries to scale.Read more

Bayer could get a bigger lift than many expect as newer medicines gain traction and farmers adopt more climate-ready crops and digital tools. But big legal claims, tougher rules, and heavy debt could still hold back the turnaround.Read more